AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...
GlobalData on MSN2mon
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized holeAbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding ... this could exceed expectations from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback